Publications by authors named "K A Gudzune"
Background: Given the evolving nature of obesity medicine, periodic evaluation of its clinical practice is needed to ensure that certification requirements address real-world experience. Practice analysis is a systematic approach to define a field's body of knowledge, and its results can inform the content outline and examination blueprint for a certification examination. This study describes the 2023 practice analysis conducted by the American Board of Obesity Medicine (ABOM).
View Article and Find Full Text PDFArticle Synopsis
- The SURMOUNT-1 trial studied the effects of tirzepatide, a medication targeting obesity, on the health-related quality of life (HRQoL) of participants.
- Participants reported significant improvements in physical function, psychosocial well-being, and overall health, with greater benefits observed in those achieving higher weight reductions.
- Results highlighted that individuals with initial physical or psychosocial limitations experienced even more pronounced improvements in their health-related quality of life.
The number and complexity of obesity treatments has increased rapidly in recent years. This is driven by the approval of new anti-obesity medications (AOMs) that produce larger degrees of weight loss than previously approved AOMs. Unfortunately, access to these highly effective therapies and to integrated team-based obesity care is limited by intra-/interpersonal patient, institutional/practitioner, community, and policy factors.
View Article and Find Full Text PDFBackground: Comprehensive medication management (CMM) programs optimize the effectiveness and safety of patients' medication regimens, but CMM may be underutilized. Whether healthcare claims data can identify patients appropriate for CMM is not well-studied.
Aim: Determine the face validity of a claims-based algorithm to prioritize patients who likely need CMM.
Importance: Obesity affects approximately 19% of women and 14% of men worldwide and is associated with increased morbidity. Antiobesity medications (AOMs) modify biological processes that affect appetite and significantly improve outcomes, such as type 2 diabetes, hypertension, and dyslipidemia.
Observations: AOMs should be administered in combination with lifestyle interventions and can be classified according to their mechanisms of action.